Evotec Receives $25 Million Milestone Payment from Bristol Myers Squibb for Progress in Neuroscience Partnership

Evotec SE, a life science company focused on accelerating drug discovery and development, announced that it has received a US$ 25 million milestone payment from Bristol Myers Squibb following scientific progress achieved under their ongoing strategic neuroscience collaboration. The payment will support continued research and development within the partnership’s joint pipeline of programs addressing neurodegenerative diseases.

Long-Term Partnership Focused on Disease-Modifying Treatments

The partnership between Evotec and Bristol Myers Squibb was established in 2016 with the aim of discovering and developing disease-modifying therapies for neurodegenerative conditions, where treatment options remain limited.

Over the years, the collaboration has yielded a robust pipeline of innovative programs, including EVT8683—in-licensed by Bristol Myers Squibb in 2021 and now known as BMS-986419—which has successfully completed Phase 1 clinical trials.

Reflecting the partners’ sustained progress and shared scientific goals, the collaboration was extended in 2023 for an additional eight years.

Scientific Leadership Perspective

“Patients living with neurodegenerative conditions urgently need therapies that go beyond symptom management,” said Dr. Cord Dohrmann, Chief Scientific Officer at Evotec. “This achievement deepens our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into therapeutic opportunities to deliver meaningful options for patients.”

About the Companies

Evotec SE is a global life science company pioneering the future of drug discovery and development. By integrating breakthrough science, AI-driven innovation, and advanced technologies, Evotec accelerates the journey from concept to cure with enhanced speed and precision.

Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases across therapeutic areas including oncology, immunology, and neuroscience.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!